Femasys Inc. (NASDAQ:FEMY) Short Interest Up 18.6% in November

Femasys Inc. (NASDAQ:FEMY) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 579,900 shares, a growth of 18.6% from the November 15th total of 489,100 shares. Approximately 2.7% of the company’s stock are short sold. Based on an average daily volume of 175,600 shares, the short-interest ratio is currently 3.3 days.

Wall Street Analyst Weigh In

Several brokerages have recently commented on FEMY. Chardan Capital reduced their price target on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Femasys in a research note on Tuesday, December 3rd.

Hedge Funds Weigh In On Femasys

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Aljian Capital Management LLC acquired a new stake in shares of Femasys during the 3rd quarter worth approximately $27,000. XTX Topco Ltd grew its stake in Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares during the last quarter. Geode Capital Management LLC increased its position in Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares during the period. Finally, CM Management LLC lifted its stake in Femasys by 6.3% in the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after buying an additional 25,000 shares during the last quarter. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Stock Performance

Femasys stock remained flat at $1.19 during mid-day trading on Friday. 93,531 shares of the company’s stock were exchanged, compared to its average volume of 321,714. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. Femasys has a 1 year low of $0.73 and a 1 year high of $2.40. The firm’s fifty day moving average is $1.14 and its 200 day moving average is $1.12. The company has a market capitalization of $27.25 million, a price-to-earnings ratio of -1.47 and a beta of -2.89.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The business had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million. On average, equities analysts expect that Femasys will post -0.84 EPS for the current fiscal year.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.